Blueberry Therapeutics is a drug discovery and development company that focuses on modern drug delivery using nanopolymer technology. The company specializes in dermatology and nanomedicine, developing innovative therapies for common dermatological disorders.

Blueberry Therapeutics

Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feel better.

Blueberry focuses on the research and development of treatments for skin diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic.

In the clinic, Blueberry uses smart, agile, clinical designs to deliver high quality trials more rapidly and with reduced development costs. 

Blueberry will rapidly progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective and safe doses with full regulatory and ethical approval.

We have programs addressing Onychomycosis,  Tinea Pedis, Acne and Atopic Dermatitis.

SBRI Healthcare

Incline Equity Partners

Connecticut Skin Institute

Medical Incubator Japan

China Medical Venture Investment (HK) Limited

Catapult Ventures

GM&C Life Sciences Fund

NPIF Maven Equity Finance

Blueberry Therapeutics Ltd

Lovely to be invited back to Staffordshire University’s Careers event last Tuesday. A delight to speak to the students and share careers advice and as always, talk about science! 
#studentengagement #careersfair #science #biosciences

Delighted to be shortlisted for the Bionow awards for Company of the Year, a ‘by invitation only’ category. Thanks to the Bionow judges for shortlisting us after an incredible year, and congratulations to our fellow finalists! https://lnkd.in/e5ZMR-JZ

Blueberry Executives, John Ridden (CEO) and Mark Hollingworth (CFO), are in San Francisco this coming week to meet with industry leaders and investors at the #DermatologySummit (tomorrow, Sunday 7th) and @JPMorgan Healthcare Conference (8th to 11th). Be sure to connect with us if you are attending – we are keen to share our innovative approaches in dermatology and discuss investment and collaborative opportunities.

#BlueberryTherapeutics #Dermatology #DermatologySummit #JPMHC42

Today we are pleased to announce that BB2603, our novel topical terbinafine antifungal product, met primary and secondary endpoints in a Phase 2b trial (BBTAF202) in 111 patients with onychomycosis.

BB2603 was superior to placebo (vehicle), with a high level of statistical significance. These antifungal effects were achieved alongside an excellent safety profile.

You can learn more here: https://lnkd.in/esGvneQh

#dermatology #clinicaldata #drugdevelopment

We’d like to extend a warm welcome to our new Laboratory Technician, Megan Dawson. Megan joins us with a Masters in Medical Microbiology from The University of Manchester, having gained lots of relevant skills in an associate practitioner role at Alder Hey Children’s Hospital. In her spare time, Megan’s interests include attending festivals and gigs, and reading (she is a huge Harry Potter fan). Welcome to Blueberry, Megan!

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 31, 2024 6:43 AM	97a03573
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	5c1cea14
crunchbase profile	general
li profile	general	Aug 31, 2024 6:43 AM	73378235
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 6:43 AM	acf01ee3
news basic	general	Aug 31, 2024 6:43 AM	f89ea87a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BLUE

COM:BLUEBERRYTHERAPEUTICS

Blueberry Therapeutics